Clinical Trials in Zabrze, Poland
29 recruiting
Showing 1–20 of 31 trials
Recruiting
Phase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Heart Failure and Impaired Kidney Function
AstraZeneca4,800 enrolled842 locationsNCT06307652
Recruiting
Not Applicable
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
HypertensionHypertension, SystolicHypertension,Essential
Orchestra BioMed, Inc500 enrolled98 locationsNCT06059638
Recruiting
Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Chronic Kidney Disease
Novo Nordisk A/S465 enrolled147 locationsNCT06717698
Recruiting
Not Applicable
Novel Setup Algorithm for Cardiac Neuromodulation Therapy
HypertensionBradycardia
BackBeat Medical Inc30 enrolled7 locationsNCT05719454
Recruiting
Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Alzheimers Disease
Hoffmann-La Roche13,000 enrolled207 locationsNCT07177352
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled158 locationsNCT07282600
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled173 locationsNCT07321886
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled386 locationsNCT06141473
Recruiting
Phase 3
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Alzheimers Disease
Hoffmann-La Roche800 enrolled120 locationsNCT07169578
Recruiting
Phase 3
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Sandoz175 enrolled40 locationsNCT06847724
Recruiting
Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Hoffmann-La Roche1,290 enrolled462 locationsNCT05595642
Recruiting
Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
Multiple Sclerosis
Hoffmann-La Roche129 enrolled32 locationsNCT05704361
Recruiting
Phase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled46 locationsNCT05877963
Recruiting
Phase 4
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Novartis Pharmaceuticals20 enrolled22 locationsNCT06444113
Recruiting
Phase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Heart Failure
AstraZeneca11,300 enrolled917 locationsNCT06677060
Recruiting
Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled721 locationsNCT05712200
Recruiting
Phase 2
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
Hoffmann-La Roche182 enrolled41 locationsNCT07074886
Recruiting
Phase 3
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
AgitationAlzheimer's Type Dementia
Suven Life Sciences Limited375 enrolled44 locationsNCT05397639